Defining the barriers to effective anti-tumor immunity in poor prognosis cancers and engineering cell therapies to break them down

Here, Bruker presents Dr. Paolo Provenzano research. Dr. Provenzano’s research program focuses on poor prognosis cancers including pancreatic cancer, which has one of the lowest survival rates of all cancers, as well as the poor prognosis subgroup of metastatic breast cancer. His lab takes a two-pronged approach to their research. The first prong is defining the barriers, both chemical and physical, to effective anti-tumor immunity - in other words, defining why certain areas of a tumor do not allow infiltration of T cells. This is a concept that Dr. Provenzano referred to as immune exclusion.